Alex Biese

One expert explains how bispecific antibodies are a ‘targeted and effective’ option for patients with multiple myeloma.

Patients with TGCT are encouraged to honestly discuss their pain with their care teams.

One expert explains the importance of a multidisciplinary care team for patients with TGCT.

TGCT is a non-malignant tumor, but one expert explained how it can similarly affect patients.

Tenosynovial giant cell tumors are not malignant but can impact patients’ quality of life, as one expert explained.

Systemic therapy and active surveillance can be viable options for patients with TGCT, as one expert explained.

Treatment with the CAR-T cell therapy Carvykti has been reported to improve survival among some patients with multiple myeloma.

The Food and Drug Administration recently approved Augtyro for the treatment of patients ages 12 and older with solid tumors harboring an NTRK gene fusion.

Following promising European trial results, a new peptide vaccine for melanoma is being studied in America, with results expected next year.

The Food and Drug Administration issued six approvals for solid tumors in June, including thyroid, endometrial, colorectal, breast and ovarian cancers.

One specialist explained the ways palliative care, also known as supportive care, can assist patients during a breast cancer journey.

Patients saw improved event-free survival and overall survival with presurgical Imfinzi and chemotherapy followed by surgery and postsurgical Imfinzi.

One expert explained the common side effects at every line of treatment for metastatic HER2-positive breast cancer during the CURE® Educated Patient® Metastatic Breast Cancer Summit.

A Biologics License Application has been filed for the subcutaneous administration of Rybrevant for some patients with non-small cell lung cancer.

One expert explains why “the future of precision medicine” has arrived in lung cancer at the CURE® Educated Patient® Lung Cancer Summit.

LGBTQI+ patients with cancer are encouraged to seek positive relationships with care teams despite possible histories of minority stress.

During the CURE® Educated Patient® Multiple Myeloma Summit, one expert explained the push to make CAR-T cell therapy available for patients sooner.

One expert explains why double autologous stem cell transplantation is a viable alternative to back-to-back transplant in high-risk multiple myeloma.

Summer is time to pay particular attention to skin issues, including for patients with cancer undergoing treatments.

Are cancer vaccines the new frontier in oncology? Experts and patients weigh in from the front lines.

Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli.

Approximately half of the patients with MDS who responded to treatment with Rytelo went a year without needing a blood transfusion, one expert explained.

As part of the CURE® Educated Patient® Summit, one expert reviewed the landscape of bispecific antibodies, such as Tecvayli, for multiple myeloma.

The immunotherapy Opvido and reirradiation resulted in a one-year progression-free survival rate of 61.7% among certain patients with head and neck cancer.

The Food and Drug Administration granted a traditional approval to Retevmo for adult and pediatric patients 2 years old and older with advanced or metastatic RET fusion-positive thyroid cancer.

Data from the MajesTEC-1 trial shows that patients with relapsed/refractory multiple myeloma responded to Tecvalyi for a median of two years and lived without disease progression for nearly a year.

As part of the “Speaking Out” series, a radiation oncologist discusses the benefits of MRI-guided stereotactic body radiation therapy.

Antibody-drug conjugates represent a paradigm shift for patients with cancer and providers.

The Food and Drug Administration has approved Rytelo to treat certain patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia.

Two years of postsurgical androgen deprivation therapy resulted in a 10-year metastasis-free survival rate of nearly 80%.